{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-24-000026","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.050373+00:00","generated_at":"2026-06-05T06:28:18.782668+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira BioSciences: FY2023 revenue $675M (+1% YoY), net income $42M; CFO to leave Sept 30","bullets":["Q4 revenue $181.2M (+5% YoY), GAAP net income $24.9M ($0.54 basic EPS), adj EBITDA $65.4M.","Full-year 2023 total revenue $675.0M (+1% YoY), GAAP net income $42.0M ($0.91 basic EPS), adj EBITDA $214.5M.","CFO Charles Reinhart to depart effective Sept 30, 2024; transition services through June 2025; search for successor underway.","2024 guidance: total revenue $680M-$705M; non-GAAP gross margin 74%-76%; R&D $70M-$80M; SG&A $245M-$265M.","FDA approved new 200L EXPAREL manufacturing suite in Feb 2024; expects commercial product later this year to benefit gross margins."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-24-000026","json":"https://secwatch.observer/filing/0001396814-24-000026.json","markdown":"https://secwatch.observer/filing/0001396814-24-000026.md","text":"https://secwatch.observer/filing/0001396814-24-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/pcrx-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:28:18.782668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16ead93c270701757771ebb0a639a724ce73bcd4","claim":"Pacira BioSciences, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue $675.0 million, net income $42.0 million, EPS $0.91 per basic share and $0.89 per diluted share.","evidence_excerpt":"a filing. --- EX-99.1 (EX-99.1) --- NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year ended December 31, 2023"},{"label":"Revenue","value":"$675.0 million"},{"label":"Net income","value":"$42.0 million"},{"label":"EPS","value":"$0.91 per basic share and $0.89 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ae364996a3","claim":"Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..","evidence_excerpt":"On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024 (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"will depart"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}